Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Adds to Migraine Drug Advice With Guidance Covering Preventive Treatments

  • Post author:PacConAdmin
  • Post published:June 1, 2023
  • Post category:Drug Industry Daily

Expanding on the clinical development of migraine drugs, the FDA has published a new draft guidance on development of drugs to prevent migraine to complement its current guidance on developing…

Continue ReadingFDA Adds to Migraine Drug Advice With Guidance Covering Preventive Treatments

Sea-Long Medical Systems Warned for Unapproved Modifications

  • Post author:PacConAdmin
  • Post published:June 1, 2023
  • Post category:Drug Industry Daily

The FDA handed Sea-Long Medical Systems a warning letter on April 4 for failing to notify the agency of expanded indications for its treatment hood device. Source: Drug Industry Daily

Continue ReadingSea-Long Medical Systems Warned for Unapproved Modifications

Novartis 483 Cites Missing Calibration, Verification Information

  • Post author:PacConAdmin
  • Post published:June 1, 2023
  • Post category:Drug Industry Daily

FDA investigators handed Novartis Farma SpA a Form 483 after finding documents missing information about equipment calibration, verification testing and software deviations. Source: Drug Industry Daily

Continue ReadingNovartis 483 Cites Missing Calibration, Verification Information

Maiden Biosciences Gets 483 for Quality System Lapses

  • Post author:PacConAdmin
  • Post published:June 1, 2023
  • Post category:Drug Industry Daily

Maiden Biosciences received a Form 483 for quality system lapses after the FDA inspected the company’s Gaithersburg, Md., facility in November 2022. Source: Drug Industry Daily

Continue ReadingMaiden Biosciences Gets 483 for Quality System Lapses

FDA Knocks Ward Photonics for Complaint Investigation Lapses

  • Post author:PacConAdmin
  • Post published:June 1, 2023
  • Post category:Drug Industry Daily

A Form 483 cites Cocoa Beach, Fla.-based Ward Photonics for continuing problems with investigation and evaluation of customer complaints for possible medical device report (MDR) requirements. Source: Drug Industry Daily

Continue ReadingFDA Knocks Ward Photonics for Complaint Investigation Lapses

FDA Cites Repeated Procedure and Document Issues at Theweb2u

  • Post author:PacConAdmin
  • Post published:June 1, 2023
  • Post category:Drug Industry Daily

Failure to resolve at least six of 10 observations from an earlier inspection resulted in another Form 483 in January for Theweb2u.com, maker of the Therapik insect bite and itch relief…

Continue ReadingFDA Cites Repeated Procedure and Document Issues at Theweb2u

FDA Adds Virtual Component to Face-to-Face Industry Meetings

  • Post author:PacConAdmin
  • Post published:June 1, 2023
  • Post category:Drug Industry Daily

Face-to-face FDA meetings may have a hybrid component beginning June 12, focusing on “having only core participants with a primary speaking role in person while others join virtually” to avoid…

Continue ReadingFDA Adds Virtual Component to Face-to-Face Industry Meetings

Adverse Events Show Slight Rise in FDA Surveillance & Epidemiology Annual Report

  • Post author:PacConAdmin
  • Post published:May 31, 2023
  • Post category:Drug Industry Daily

CDER’s Office of Surveillance and Epidemiology (OSE) 2022 Annual Report showed the total number of adverse event (AE) reports rose slightly from 2.23 million in 2021 to 2.34 million, capturing…

Continue ReadingAdverse Events Show Slight Rise in FDA Surveillance & Epidemiology Annual Report

Program Offers Devicemakers up to $300K for Using Advanced Technologies

  • Post author:PacConAdmin
  • Post published:May 31, 2023
  • Post category:Drug Industry Daily

The FDA and the Medical Device Innovation Consortium (MDIC) are collaborating to offer funding of up to $300,000 to medical devicemakers that use advanced technologies to enhance product quality or…

Continue ReadingProgram Offers Devicemakers up to $300K for Using Advanced Technologies

Meeting Planner — Week of May 29, 2023

  • Post author:PacConAdmin
  • Post published:May 31, 2023
  • Post category:Drug Industry Daily

Upcoming events in the coming weeks include six FDA advisory committee meetings as well as webinars and conferences on subjects ranging from advanced gene and cell therapy, ICH E8 R1…

Continue ReadingMeeting Planner — Week of May 29, 2023
  • Go to the previous page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.